Emerging antibody-based therapies for Huntington’s disease: current status and perspectives for future development

References

• Medina A, Mahjoub Y, Shaver L, et al. Prevalence and incidence of Huntington’s disease: an updated systematic review and meta-analysis. Mov Disord. 2022;37(12):2327–2335. doi: 10.1002/mds.29228. Epub 2022 Sep 26. PMID: 36161673; PMCID: PMC10086981.
   PubMed Web of Science ®Google Scholar
• Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington’s disease. Nature. 1983;306(5940):234–238. doi: 10.1038/306234a0
   PubMed Web of Science ®Google Scholar
• Macdonald M, HD Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971–983. doi: 10.1016/0092-8674(93)90585-E
   PubMed Web of Science ®Google Scholar
• Grody WW, Deignan JL. Diagnostic Molecular Genetics. In: Pyeritz R, Korf B, and Grody W, editors. Emery and Rimoin’s principles and practice of medical genetics and genomics. 7th ed. Cambridge, MA, USA: Elsevier; 2019. p. 165–203.
   Google Scholar
• Ranen NG, Stine OC, Abbott MH, et al. Anticipation and instability of IT-15 (Cag)n repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet. 1995;57(3):593–602.
   PubMed Web of Science ®Google Scholar
• Fusilli C, Migliore S, Mazza T, et al. Biological and clinical manifestations of juvenile Huntington’s disease: a retrospective analysis. The Lancet Neurology. 2018;17(11):986–993. doi: 10.1016/S1474-4422(18)30294-1
   PubMed Web of Science ®Google Scholar
• Bashir H, Jankovic J. Treatment options for chorea. Expert Rev Neurother. 2018;18:51–63. doi: 10.1080/14737175.2018.1403899
   PubMed Web of Science ®Google Scholar
• Kumar A, Kumar V, Singh K, et al. Therapeutic advances for Huntington’s disease. Brain Sci. 2020;10(1):43. doi: 10.3390/brainsci10010043
   PubMed Web of Science ®Google Scholar
• Barnat M, Le Friec J, Benstaali C, et al. Huntingtin-mediated multipolar-bipolar transition of newborn cortical neurons is critical for their postnatal neuronal morphology. Neuron. 2017;93(1):99–114. doi: 10.1016/j.neuron.2016.11.035
   PubMed Web of Science ®Google Scholar
• Jurcau A. Molecular pathophysiological mechanisms in Huntington’s disease. Biomedicines. 2022;10:1432. doi: 10.3390/biomedicines10061432
   PubMed Web of Science ®Google Scholar
• Saudou F, Humbert S. The biology of huntingtin. Neuron. 2016;89(5):910–926. doi: 10.1016/j.neuron.2016.02.003
   PubMed Web of Science ®Google Scholar
• Kang R, Wang L, Sanders SS, et al. Altered regulation of striatal neuronal N-methyl-D-aspartate receptor trafficking by palmitoylation in Huntington disease mouse model. Front Synaptic Neurosci. 2019;11:3. doi: 10.3389/fnsyn.2019.00003
   PubMed Web of Science ®Google Scholar
• Groc L, Choquet D. Linking glutamate receptor movements and synapse function. Science. 2020;368(6496):eaay4631. doi: 10.1126/science.aay4631
   PubMed Web of Science ®Google Scholar
• Hassel B, Tessler S, Faull RL, et al. Glutamate uptake is reduced in prefrontal cortex in Huntington’s disease. Neurochem Res. 2008;33(2):232–237. doi: 10.1007/s11064-007-9463-1
   PubMed Web of Science ®Google Scholar
• Yablonska S, Ganesan V, Ferrando LM, et al. Mutant huntingtin disrupts mitochondrial proteostasis by interacting with TIM23. Proc Natl Acad Sci USA. 2019;116:16593–16602. doi: 10.1073/pnas.1904101116
   PubMed Web of Science ®Google Scholar
• Jurcau A, Jurcau CM. Mitochondria in Huntington’s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies. Neural Regen Res. 2023;18(7):1472–1477. doi: 10.4103/1673-5374.360289
   PubMed Web of Science ®Google Scholar
• Woo JH, Cho H, Seol YH, et al. Power failure of mitochondria and oxidative stress in neurodegeneration and its computational model. Antioxidants. 2021;10(2):229. doi: 10.3390/antiox10020229
   Web of Science ®Google Scholar
• Mackay JP, Nasrallah WB, Raymond LA. Cause or compensation?—Altered neuronal Ca 2+ handling in Huntington’s disease. CNS Neurosci Ther. 2018;24(4):301–310. doi: 10.1111/cns.12817
   PubMed Web of Science ®Google Scholar
• Chang DT, Rintoul GL, Pandipati S, et al. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobio Dis. 2006;22(2):388–400. doi: 10.1016/j.nbd.2005.12.007
   PubMed Web of Science ®Google Scholar
• Sawant N, Morton H, Kshirsagar S, et al. Mitochondrial abnormalities and synaptic damage in Huntington’s disease: a focus on defective mitophagy and mitochondria-targeted therapeutics. Mol Neurobiol. 2021;58:6350–6377. doi: 10.1007/s12035-021-02556-x
   PubMed Web of Science ®Google Scholar
• Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev. 2010;90(3):905–981.
   PubMed Web of Science ®Google Scholar
• Dubois C, Kong G, Tran H, et al. Small non-coding RNAs are dysregulated in Huntington’s disease transgenic mice independently of the therapeutic effects of an environmental intervention. Mol Neurobiol. 2021;58(7):3308–3318. doi: 10.1007/s12035-021-02342-9
   PubMed Web of Science ®Google Scholar
• Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science. 2001;293(5529):493–498. doi: 10.1126/science.1059581
   PubMed Web of Science ®Google Scholar
• Hay DG, Sathasiwam K, Tobaben S, et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington’s disease and induction of stress proteins as a therapeutic approach. Human Molecular Genetics. 2004;13(13):1389–1405. doi: 10.1093/hmg/ddh144
   PubMed Web of Science ®Google Scholar
• Bhutani N, Venkatraman P, Goldberg AL. Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation. EMBO J. 2007;26:1385–1396. doi: 10.1038/sj.emboj.7601592
   PubMed Web of Science ®Google Scholar
• Harding RJ, Tong YF. Proteostasis in Huntington’s disease: disease mechanisms and therapeutic opportunities. Acta Pharmacol Sinica. 2018;39(5):754–769. doi: 10.1038/aps.2018.11
   PubMed Web of Science ®Google Scholar
• Davies SW, Turmaine M, Cozens BA, et al. Formation of intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537–548. doi: 10.1016/s0092-8674(00)80513-9
   PubMed Web of Science ®Google Scholar
• Slow EJ, Graham RK, Osmand AP, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci, USA. 2005;102(32):11402–11407. doi: 10.1073/pnas.0503634102
   PubMed Web of Science ®Google Scholar
• Sica RE. Could astrocytes be the primary target of an offending agent causing the primary degenerative diseases of the human central nervous system? A hypothesis. Med Hypotheses. 2015;84(5):481–489. doi: 10.1016/j.mehy.2015.02.004
   PubMed Web of Science ®Google Scholar
• Gratuze M, Cisbani G, Cicchetti F, et al. Is Huntington’s disease a tauopathy? Brain. 2016;139(Pt 4):1014–1025. doi: 10.1093/brain/aww021
   PubMed Web of Science ®Google Scholar
• Maxan A, Cicchetti F. Tau: a common denominator and therapeutic target for neurodegenerative disorders. J Exp Neurosci. 2018;12:1–4. doi: 10.1177/1179069518772380
   Google Scholar
• St-Amour I, Turgeon A, Goupil C, et al. Co-occurrence of mixed proteinopathies in late-stage Huntington’s disease. Acta Neuropathol. 2018;135(2):249–65. doi: 10.1007/s00401-017-1786-7
   PubMed Web of Science ®Google Scholar
• Messer A, Butler DC. Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders. Neurobiol Dis. 2020;13:104619.
   Google Scholar
• Bashir H. Emerging therapies in Huntington’s disease. Expert Rev Neurother. 2019;19(10):983–995. doi: 10.1080/14737175.2019.1631161
   PubMed Web of Science ®Google Scholar
• Jarosińska OD, Rüdiger SGD. Molecular strategies to target protein aggregation in Huntington’s disease. Front Mol Biosci. 2021;8:769184.
   PubMed Web of Science ®Google Scholar
• Schleidgen S, Dederer HG, Sgodda S, et al. Human germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy. BMC Med Ethics. 2020;21(1):87. doi: 10.1186/s12910-020-00487-1
   PubMed Web of Science ®Google Scholar
• Mittelman D, Moye C, Morton J, et al. Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells. Proc Natl Acad Sci USA. 2009;106(24):9607–9612. doi: 10.1073/pnas.0902420106
   PubMed Web of Science ®Google Scholar
• Wild EJ, Tabrizi S. Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. 2017;16(10):837–847.
   PubMed Web of Science ®Google Scholar
• Dabrowska M, Juzwa W, Krzyosiak WJ, et al. Precise excision of the CAG tract from the huntingtin gene by Cas9 nickases. Front Neurosci. 2018;12:75. doi: 10.3389/fnins.2018.00075
   PubMed Web of Science ®Google Scholar
• Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21(2):121–131. doi: 10.1038/nm.3793
   PubMed Web of Science ®Google Scholar
• Schaefer KA, Wu WH, Colgan DF, et al. Unexpected mutations after CRISPR–Cas9 editing in vivo. Nat Methods. 2017;14(6):547–548. doi: 10.1038/nmeth.4293
   PubMed Web of Science ®Google Scholar
• Ferguson MW, Kennedy CJ, Palpagama TH, et al. Current and possible future therapeutic options for Huntington’s disease. J Cent Nerv Syst Dis. 2022;14:11795735221092517. doi: 10.1177/11795735221092517
   Web of Science ®Google Scholar
• Fink KD, Deng P, Gutierrez J, et al. Allele-specific reduction of the mutant huntingtin allele using transcription activator-like effectors in human Huntington’s disease fibroblasts. Cell Transplant. 2016;25:677–686. doi: 10.3727/096368916X690863
   PubMed Web of Science ®Google Scholar
• Jurcau A, Jurcau MC. Therapeutic strategies in Huntington’s disease: from genetic defect to gene therapy. Biomedicines. 2022;10:1895. doi: 10.3390/biomedicines10081895
   PubMed Web of Science ®Google Scholar
• Silva AC, Lobo DD, Martins IM, et al. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders. Brain. 2020;143(2):407–429. doi: 10.1093/brain/awz328
   PubMedGoogle Scholar
• Rook ME, Southwell AL. Antisense oligonucleotide therapy: from design to the Huntington disease clinic. BioDrugs. 2022;36(2):105–119. doi: 10.1007/s40259-022-00519-9
   PubMed Web of Science ®Google Scholar
• Alterman JF, Godinho BMDC, Hassler MR, et al. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat Biotechnol. 2019;37:884–894. doi: 10.1038/s41587-019-0205-0
   PubMed Web of Science ®Google Scholar
• Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci USA. 2005;102(16):5820–5825. doi: 10.1073/pnas.0501507102
   PubMed Web of Science ®Google Scholar
• Franich NR, Fitzsimons HL, Fong DM, et al. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington’s disease. Mol Ther. 2008;16(5):947–956. doi: 10.1038/mt.2008.50
   PubMed Web of Science ®Google Scholar
• Miniarikova J, Zanella I, Huseinovic A, et al. Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington’s disease. Mol Ther Nucleic Acids. 2016;5:e297. doi: 10.1038/mtna.2016.7
   PubMedGoogle Scholar
• Homepage on the internet. [cited 2023 Oct 31]. Available from: www.clinicaltrials.gov
   Google Scholar
• Stanek LM, Sardi SP, Mastis B, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum Gene Ther. 2014;25(5):461–474. doi: 10.1089/hum.2013.200
   PubMed Web of Science ®Google Scholar
• Willis TA. Therapeutic advances in spinal muscular atrophy. Paediatrics Child Health. 2023;33:23–28. doi: 10.1016/j.paed.2022.12.010
   Google Scholar
• Liu X, Valentine SJ, Plasencia MD, et al. Mapping the human plasma proteome by SCX-LC-IMS-MS. J Am Soc Mass Spectrom. 2007;18(7):1249–1264. doi: 10.1016/j.jasms.2007.04.012
   PubMed Web of Science ®Google Scholar
• Wild EJ, Boggio R, Langbehn D, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J Clin Invest. 2015;125(5):1979–86. doi: 10.1172/JCI80743
   PubMed Web of Science ®Google Scholar
• Masnata M, Sciacca G, Maxan A, et al. Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms. Acta Neuropathol. 2019;137(6):981–1001. doi: 10.1007/s00401-019-01973-6
   PubMed Web of Science ®Google Scholar
• Jamwal S, Elsworth JD, Rahi V, et al. Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives. Expert Rev Neurother. 2020;20(11):1123–1141. doi: 10.1080/14737175.2020.1801424
   PubMed Web of Science ®Google Scholar
• Denis HL, David LS, Cicchetti F. Antibody-based therapies for Huntington’s disease: current status and future directions. Neurobiol Dis. 2019;132:104569. doi: 10.1016/j.nbd.2019.104569
   PubMed Web of Science ®Google Scholar
• Miguez A, Gomis C, Vila C, et al. Soluble mutant huntingtin drives early human pathogenesis in Huntington’s disease. Cell Mol Life Sci. 2023;80(8):238. doi: 10.1007/s00018-023-04882-w
   PubMed Web of Science ®Google Scholar
• Alpaugh M, Cicchetti F. A brief history of antibody-based therapy. Neurobiol Dis. 2019;130:104504. doi: 10.1016/j.nbd.2019.104504
   PubMed Web of Science ®Google Scholar
• Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125:S41–S52. doi: 10.1016/j.jaci.2009.09.046
   PubMed Web of Science ®Google Scholar
• Asaadi Y, Jouneghani FF, Janani S, et al. A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomark Res. 2021;9:87. doi: 10.1186/s40364-021-00332-6
   PubMed Web of Science ®Google Scholar
• Ward ES, Güssow D, Griffiths AD, et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989;341(6242):544–546. doi: 10.1038/341544a0
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–448. doi: 10.1038/363446a0
   PubMed Web of Science ®Google Scholar
• Konning D, Zielonka S, Grzeschik J, et al. Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol. 2017;45:10–16. doi: 10.1016/j.sbi.2016.10.019
   PubMed Web of Science ®Google Scholar
• Wagner TR, Rothbauer U. Nanobodies Right in the middle: intrabodies as toolbox to visualize and modulate antigens in the living cell. Biomolecules. 2020;10(12):1701. doi: 10.3390/biom10121701
   PubMed Web of Science ®Google Scholar
• Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019;102:263. doi: 10.1016/j.neuron.2019.03.020
   PubMed Web of Science ®Google Scholar
• Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803. doi: 10.3389/fimmu.2022.975803
   PubMed Web of Science ®Google Scholar
• Chia KY, Ng KY, Koh RY, et al. Single-chain fv antibodies for targeting neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2018;17(9):671–679. doi: 10.2174/1871527317666180315161626
   PubMed Web of Science ®Google Scholar
• Colby DW, Chu Y, Cassady JP, et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A. 2004;101(51):17616–17621. doi: 10.1073/pnas.0408134101
   PubMed Web of Science ®Google Scholar
• Butler DC, Joshi SN, Genst E, et al. Bifunctional anti-non-amyloid component α-synuclein nanobodies are protective in situ. PloS One. 2016;11(11):e0165964. doi: 10.1371/journal.pone.0165964
   PubMed Web of Science ®Google Scholar
• Cattaneo A, Chirichella M. Targeting the post-translational proteome with intrabodies. Trends Biotechnol. 2019;37(6):578–591. doi: 10.1016/j.tibtech.2018.11.009
   PubMed Web of Science ®Google Scholar
• Paganetti P, Calanca V, Galli C, et al. Beta-site specific intrabodies to decrease and prevent generation of Alzheimer’s abeta peptide. J Cell Bio. 2005;168(6):863–868. doi: 10.1083/jcb.200410047
   PubMed Web of Science ®Google Scholar
• Böldicke T. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J Cell Mol Med. 2007;11(1):54–70. doi: 10.1111/j.1582-4934.2007.00002.x
   PubMed Web of Science ®Google Scholar
• Zhang C, Ötjengerdes RM, Roewe J, et al. Applying antibodies inside cells: principles and recent advances in neurobiology, virology and oncology. BioDrugs. 2020;34(4):435–462. doi: 10.1007/s40259-020-00419-w
   PubMed Web of Science ®Google Scholar
• Carlson JR. A new means of inducibly inactivating a cellular protein. Mol Cell Biol. 1988;8(6):2638–2646. doi: 10.1128/mcb.8.6.2638-2646.1988
   PubMed Web of Science ®Google Scholar
• Lecerf JM, Shirley TL, Zhu Q, et al. Human single-chain fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington’s disease. PNAS. 2001;98(8):4764–4769. doi: 10.1073/pnas.071058398
   PubMed Web of Science ®Google Scholar
• Duennwald ML, Jagadish S, Muchowski PJ, et al. Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci USA. 2006;103(29):11045–11050. doi: 10.1073/pnas.0604547103
   PubMed Web of Science ®Google Scholar
• Khoshnan A, Ko J, Patterson PH. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci USA. 2002;99(2):1002–1007.
   PubMed Web of Science ®Google Scholar
• Legleiter J, Lotz GP, Miller J, et al. Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J Biol Chem. 2009;284(32):21647–21658. doi: 10.1074/jbc.M109.016923
   PubMed Web of Science ®Google Scholar
• Hoffner G, Dijan P. Polyglutamine aggregation in Huntington’s disease: does structure determine toxicity? Mol Neurobiol. 2015;52(3):1297–1314. doi: 10.1007/s12035-014-8932-1
   PubMed Web of Science ®Google Scholar
• Nagai Y, Inui T, Popiel HA, et al. A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol. 2007;14(4):332–340. doi: 10.1038/nsmb1215
   PubMed Web of Science ®Google Scholar
• Khoshnan A, Southwell AL, Bugg CW, et al. Recombinant intrabodies as molecular tools and potential therapeutics for Huntington’s disease. In: Lo D, and Hughes R, editors. Neurobiology of Huntington’s disease: applications to drug discovery. Boca Raton: CRC Press/Taylor&Francis; 2011. p. 255–266. Chapter 10.
   Google Scholar
• Kim YE, Hosp F, Frottin F, et al. Soluble oligomers of PolyQ-expanded huntingtin target a multiplicity of key cellular factors. Mol Cell. 2016;63(6):951–964. doi: 10.1016/j.molcel.2016.07.022
   PubMed Web of Science ®Google Scholar
• Qin ZH, Wang Y, Sapp E, et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci. 2004;24(1):269–281. doi: 10.1523/JNEUROSCI.1409-03.2004
   PubMed Web of Science ®Google Scholar
• Southwell AL, Khoshnan A, Dunn DE, et al. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci. 2008;28(36):9013–9020. doi: 10.1523/JNEUROSCI.2747-08.2008
   PubMed Web of Science ®Google Scholar
• Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington’s disease. J Neurosci. 2009;29(43):13589–13602. doi: 10.1523/JNEUROSCI.4286-09.2009
   PubMed Web of Science ®Google Scholar
• Amaro IA, Henderson LA. An intrabody drug (rAAV6-INT41) reduces the binding of N-terminal huntingtin fragment(s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6/2 animal model. J Neurodegener Dis. 2016;7120753. doi: 10.1155/2016/7120753. Epub 2016 Aug 10. PMID: 27595037; PMCID: PMC4995342.
   Google Scholar
• Wang CE, Zhou H, McGuire JR, et al. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Bio. 2008;181(5):803–816. doi: 10.1083/jcb.200710158
   PubMed Web of Science ®Google Scholar
• Wolfgang WJ, Miller TW, Webster JM, et al. Suppression of Huntington’s disease pathology in drosophila by human single-chain fv antibodies. Proc Natl Acad Sci USA. 2005;102(32):11563–11568. doi: 10.1073/pnas.0505321102
   PubMed Web of Science ®Google Scholar
• Snyder-Keller A, McLear JA, Hathorn T, et al. Early or late-stage anti N-terminal huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J Neuropathol Exp Neurol. 2010;69:1078–1085. doi: 10.1097/NEN.0b013e3181f530ec
   PubMed Web of Science ®Google Scholar
• Manoutcharian K, Perez-Garmendia R, Gevorkian G. Recombinant antibody fragments for neurodegenerative diseases. Curr Neuropharmacol. 2017;15(5):779–788. doi: 10.2174/1570159X01666160930121647
   PubMed Web of Science ®Google Scholar
• Butler DC, Snyder-Keller A, De Genst E, et al. Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington’s disease. Protein Eng Des Sel. 2014;27(10):359–363. doi: 10.1093/protein/gzu041
   PubMed Web of Science ®Google Scholar
• Zha J, Liu XM, Zhu J, et al. A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses. Sci Rep. 2016;6:36631. doi: 10.1038/srep36631
   PubMed Web of Science ®Google Scholar
• Kwam JK, Nannenga BL, Wang MS, et al. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One. 2009;4(5):e5727. doi: 10.1371/journal.pone.0005727
   PubMed Web of Science ®Google Scholar
• Messer A, Joshi SN. Intrabodies as neuroprotective therapeutics. Neurotherapeutics. 2013;10:447–458. doi: 10.1007/s13311-013-0193-6
   PubMed Web of Science ®Google Scholar
• Jurcau A. Insights into the pathogenesis of neurodegenerative diseases: focus on mitochondrial dysfunction and oxidative stress. Int J Mol Sci. 2021;22:11847. doi: 10.3390/ijms222111847
   PubMed Web of Science ®Google Scholar
• Reichsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci. 1996;21(7):267–271.
   PubMed Web of Science ®Google Scholar
• Butler DC, Messer A. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One. 2011;6(12):e29199.
   PubMed Web of Science ®Google Scholar
• Chatterjee D, Bhatt M, Butler D, et al. Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model. NPJ Parkinsons Dis. 2018;4:25. doi: 10.1038/s41531-018-0062-4
   PubMed Web of Science ®Google Scholar
• Clift D, McEwan WA, Labzin LI, et al. A method for the acute and rapid degradation of endogenous proteins. Cell. 2017;171(7):1692–1706.e18. doi: 10.1016/j.cell.2017.10.033
   PubMed Web of Science ®Google Scholar
• Tomoshige S, Nomura S, Ohgane K, et al. Discovery of small molecules that induce the degradation of huntingtin. Angew Chem Int Ed Engl. 2017;56:11530–11533. doi: 10.1002/anie.201706529
   PubMed Web of Science ®Google Scholar
• Tomoshige S, Nomura S, Ohgane K, et al. Degradation of huntingtin mediated by a hybrid molecule composed of IAP antagonist linked to phenyldiazenyl benzothiazole derivative. Bioorg Med Chem Lett. 2018;28(4):707–710. doi: 10.1016/j.bmcl.2018.01.012
   PubMed Web of Science ®Google Scholar
• Lu XH, Yang XW. “Huntingtin holiday”: progress toward an antisense therapy for Huntington’s disease. Neuron. 2012;74:964–966. doi: 10.1016/j.neuron.2012.06.001
   PubMed Web of Science ®Google Scholar
• Bartl S, Oueslati A, Southwell AL, et al. Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: implications for the treatment of Huntington’s disease. Neurobiol Dis. 2020;141:104943. doi: 10.1016/j.nbd.2020.104943
   PubMed Web of Science ®Google Scholar
• Miller TW, Shirley TL, Wolfgang WJ, et al. DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Ther. 2003;7(5 Pt 1):572–579. doi: 10.1016/s1525-0016(03)00063-7
   PubMed Web of Science ®Google Scholar
• Ramsingh AI, Manley K, Rong Y, et al. Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington’s disease. Hum Mol Genet. 2015;24(21):6186–6197. doi: 10.1093/hmg/ddv335
   PubMed Web of Science ®Google Scholar
• Cisbani G, Maxan A, Kordower JH, et al. Presence of tau pathology within foetal neural allografts in patients with Huntington’s and Parkinson’s disease. Brain. 2017;140(11):2982–2992. doi: 10.1093/brain/awx255
   PubMedGoogle Scholar
• Reetz K, Giehl K, Dogan I, et al. D26 Pathological tau signal in huntington’s disease – an in vivo [18F]-AV-1451 pet imaging report. J Neurol Neurosurg Psychiatry. 2016;87(Suppl 1):A44.1–A44. doi: 10.1136/jnnp-2016-314597.125
   Google Scholar
• Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402–414. doi: 10.1016/j.neuron.2013.07.046
   PubMed Web of Science ®Google Scholar
• Boutajangout A, Ingadottir J, Davies P, et al. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011;118(4):658–667. doi: 10.1111/j.1471-4159.2011.07337.x
   PubMed Web of Science ®Google Scholar
• Alpaugh M, Masnata M, de Rus Jacquet A, et al. Passive immunization against phosphorylated tau improves features of Huntington’s disease pathology. Mol Ther. 2022;30(4):1500–1522. doi: 10.1016/j.ymthe.2022.01.020
   PubMed Web of Science ®Google Scholar
• Sun CS, Lee CC, Li YN, et al. Conformational switch of polyglutamine-expanded huntingtin into benign aggregates leads to neuroprotective effect. Sci Rep. 2015;5:14992. doi: 10.1038/srep14992
   PubMed Web of Science ®Google Scholar
• Wilton DK, Mastro K, Heller MD, et al. Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington’s disease. Nat Med. 2023. doi: 10.1038/s41591-023-02566-3
   Web of Science ®Google Scholar
• Kumar R, Claassen D, Mongan A, et al. A phase 2 open-label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of Intravenous ANX005 in patients with, or at risk of, manifest Huntington’s disease (HD) (S32.009). Neurology. 2023;100(17_supplement_2):3366. doi: 10.1212/WNL.0000000000203217
   Web of Science ®Google Scholar
• Leonard JE, Fisher TL, Winter LA, et al. Nonclinical safety evaluation of VX15/2503, a humanized Ig4 anti-SEMAD antibody. Mol Cancer Therapeut. 2015;14(4):964. doi: 10.1158/1535-7163.MCT-14-0924
   PubMed Web of Science ®Google Scholar
• Southwell AL, Franciosi S, Villanueva EB, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington’s disease. Neurobiol Dis. 2015;76:46–56. doi: 10.1016/j.nbd.2015.01.002
   PubMed Web of Science ®Google Scholar
• Feigin A, Evans EE, Fisher TL, et al. Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2022;28(10):2183–2193. doi: 10.1038/s41591-022-01919-8
   PubMed Web of Science ®Google Scholar
• Andronie-Cioara FL, Ardelean AI, Nistor-Cseppento CD, et al. Molecular mechanisms of neuroinflammation in aging and Alzheimer’s disease progression. Int J Mol Sci. 2023;24:1869. doi: 10.3390/ijms24031869
   PubMedGoogle Scholar
• Pido-Lopez J, Tanudjojo B, Farag S, et al. Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington’s disease by etanercept treatment. Sci Rep. 2019;9(1):7202. doi: 10.1038/s41598-019-43627-3
   PubMedGoogle Scholar
• Rabinovici GD, La Joie R. Amyloid-targeting monoclonal antibodies for alzheimer disease. JAMA. 2023;330(6):507–509. doi: 10.1001/jama.2023.11703
   PubMed Web of Science ®Google Scholar
• Jeremic D, Navarro-López JD, Jiménez-Díaz L. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer’s disease phase III clinical trials: a systematic review and interactive web app-based meta-analysis. Ageing Res Rev. 2023;90:102012. doi: 10.1016/j.arr.2023.102012
   PubMed Web of Science ®Google Scholar
• Ananbeh H, Kupkova Skalnikova H. Extracellular vesicles as possible sources of Huntington’s disease biomarkers. In: Thomas E Parkin G, editors. Biomarkers for Huntington’s disease. Contemporary clinical neuroscience. Cham: Springer; 2023. p. 45–75.
   Google Scholar
• Zeun P, Scahill RI, Tabrizi SJ, et al. Fluid and imaging biomarkers for Huntington’s disease. Mol Cell Neurosci. 2019;97:67–80.
   PubMed Web of Science ®Google Scholar
• Wexler A. Stigma, history, and Huntington’s disease. The Lancet. 2010;376(9734):18–19. doi: 10.1016/S0140-6736(10)60957-9
   PubMed Web of Science ®Google Scholar